{"entity":{"id":"nct05786924","kind":"trial","name":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies","aka":[],"tldr":"A phase 1/2 trial of fOLFIRI (5-FU, leucovorin, irinotecan), cetuximab, panitumumab, gemcitabine and other drugs in colorectal cancer, run by Institut de Recherches Internationales Servier, now recruiting.","summary":"Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies is a phase 1/2, interventional study registered as NCT05786924 by Institut de Recherches Internationales Servier, with a registry enrolment figure of 554 participants, started 2023-04-18 and due to reach its primary completion in 2028-06. Interventions recorded: S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D. Primary outcome: Dose Escalation: Incidence of dose-limiting toxicities (DLTs); Dose Escalation: Number of Adverse Events (AEs) and Serious Adverse Events (SAEs); Dose Optimization/Expansion: Objective response (OR). Colorectal eligibility wording from the registry: \"* Part 1D: Colorectal adenocarcinoma with KRAS, HRAS, NRAS, BRAF, and/or CRAF (RAF1) mutations or alterations\". Sites: Australia, China, Denmark, France, Hong Kong, Italy, Japan, Spain, United Kingdom, United States. United Kingdom sites listed: 3. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05786924","url":"https://clinicaltrials.gov/study/NCT05786924"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","braf-v600e-colorectal","kras-g12c-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","monoclonal-antibody","topoisomerase-inhibitors"],"targets":[],"drugs":["folfiri","cetuximab","panitumumab","gemcitabine","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): University College London Hospital (London); Hammersmith Hospital (London); The Christie NHS Foundation Trust (Manchester)."],"nct":"NCT05786924","phase":"1/2","setting":"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies","sponsor":"Institut de Recherches Internationales Servier","enrolled":554,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05786924/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"panitumumab","kind":"drug","name":"Panitumumab","route":"/drugs/panitumumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}